Spring Bank Pharmaceuticals (SBPH) PT Lowered to $25 at Chardan Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spring Bank Pharmaceuticals (SBPH) PT Cut At Cantor After Inarigivir Lauch Delay
March 11, 2019 9:27 AM EDTCantor Fitzgerald analyst, Elemer Piros, reiterated his Overweight rating on shares of Spring Bank Pharmaceuticals (NASDAQ: SBPH) but cut his price target to $29 from $34 on the company moving the U.S. inarigivir launch to 2022 from 2021 and Europe to 2023.
The analyst stated "The probability-adjusted (30%), fully... More
